|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prognostic value of carcinoembryonicantigen and vascular endothelial growth factor tumor tissue content in colorectal canccr显示文摘 | Ferroni P Palmirotta R Spila A | 2006 | Oncology2006，71，34： | 1 |
| 2 | Plastic power sour-ces显示文摘 | Appetecchi G B Panero S Spila E | 1998 | J Appliedelectrochemistry1998，28，： | 1 |
| 3 | Clinical utility of CA72-4 serum marker in the stage and immediate post-surgical management of gas- tric cancer patients显示文摘 | Spila A Roselli M Cosimelli M | 1996 | Anticancer Res1996，16，： | 1 |
| 4 | Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer显示文摘 | Ferroni P Palmirotta R Spila A | 2006 | Oncolo-gy2006，71，34： | 1 |
| 5 | Absorptive Capacity,Innovation Networks and Products:SME in the Basque Country显示文摘 | Spila J C Rocca L Ibarra A | 2010 | International Journal of Innovation and Regional Development2010，，3： | 1 |
| 6 | Bioavailability to rats of selenium in milk of cows fed sodium selenite or selenited barley显示文摘 | A spila P Mykkanen H M | 1986 | Ann Nutr1986，30，3： | 1 |
| 7 | Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients显示文摘 | FERRONI P ROSELLI M SPILA A | | 0，，12： | 1 |
| 8 | Clinical utility of CA 72-4serum marker in the staging and immediate pt?t-suipcalmanagement of gastric cancer patients显示文摘 | Spila A Roselli M Cosimelli M | 1996 | Anticancer Res1996，16，： | 1 |
| 9 | Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer显示文摘AIM To investigate the possible predictive role of routinely used glycemic parameters for a first venous thromboembolism(VTE) episode in gastrointestinal(GI) cancer ambulatory patients-with or without clinically diagnosed type 2 diabetes(T2D) or obesity-treated with chemotherapy.METHODS Pre-treatment fasting blood glucose,insulin,glycated hemoglobin(Hb A1c) and homeostasis model of risk assessment(HOMA) were retrospectively evaluated in a cohort study of 342 GI cancer patients. Surgery was performed in 142(42%) patients with primary cancer,30(21%) and 112(79%) of whom received neoadjuvant and adjuvant therapies,respectively. Firstline chemotherapy was administered in 200(58%) patients with metastatic disease. The study outcome was defined as the occurrence of a first symptomatic or asymptomatic VTE episode during active treatment.RESULTS Impaired glucose tolerance(IGT) or T2 D were diagnosed in 30% of GI cancer patients,while overweight/obesity had an incidence of 41%. VTE occurred in 9.4% of patients(7% of non-diabetic non-obese),especially in those with a high ECOG score(P = 0.025). No significant association was found between VTE incidence and T2 D,obesity,different tumor types,metastatic disease,Khorana class of risk,or different anti-cancer drugs,although VTE rates were substantially higher in patients receiving bevacizumab(17% vs 8%,P = 0.044). Conversely,all glucose metabolic indexes were associated with increased VTE risk at ROC analysis. Multivariate Cox proportional analyses confirmed that HOMA index(HR = 4.13,95%CI: 1.63-10.5) or fasting blood glucose(HR = 3.56,95%CI: 1.51-8.39) were independent predictors of VTE occurrence during chemotherapy.CONCLUSION The results here reported demonstrate that evaluating glucose metabolic asset may allow for VTE risk stratification in GI cancer,helping to identify chemotherapy-treated patients who might benefit from thromboprophylaxis. Further multicenter prospective studies involving a larger number of patients are presently needed. | Fiorella Guadagni Silvia Riondino Vincenzo Formica Girolamo Del Monte Anna Maria Morelli Jessica Lucchetti Antonella Spila Roberta D’Alessandro David Della-Morte Patrizia Ferroni Mario Roselli | 2017 | World Journal of Gastroenterology2017，23，28： | 1 |
| 10 | Clinical utility of CA724 serum marker in the stage and immediate post-surgical management of gas- tric cancer patients显示文摘 | Spila A Roseli M Cosimeli M | 1996 | Anticancer Res1996，16，4： | 1 |
| 11 | Prognostic value of vascular endothelial growth factor tmnor tissue content of colorectal cancer显示文摘 | FERRONI P SPILA A MARTINI F | 2005 | Oncology2005，69，2： | 1 |
| 12 | Clinical utility of CA72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients 显示文摘 | Spila A Roselli M Cosimelli M et d | 1996 | Anticancer Res1996，16，4： | 1 |
| 13 | Solid state supercapacitors using gel membranes as electrolytes显示文摘 | Panero S Clemente A Spilae E | 1996 | Solid State Ionics1996，8688，： | 1 |
| 14 | Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer显示文摘 | Ferroni P Spila A Martini F | 2005 | Oncology2005，69，2： | 1 |
| 15 | Plastic power sources显示文摘 | PANERO S SPILA E | 1998 | J Appl Electrochem1998，28，： | 1 |
| 16 | Prognostic value of vascular endothelial growth factor tumor tissue content of coloreetal cancer显示文摘 | Ferroni P Spila A Martini F | 2005 | Oncology2005，69，2： | 1 |
| 17 | Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, part I显示文摘 | Dr. Fiorella Guadagni M.D. Mario Roselli M.D. Maurizio Cosimelli M.D. Antonella Spila Ph.D. Francesco Cavaliere M.D. Raffaella Arcuri M.D. Maria Rosaria Abbolito Ph.D. John W. Greiner Ph.D. Jeffrey Schlom Ph.D | 1994 | Diseases of the Colon & Rectum1994，，2： | 1 |
| 18 | Plateletactivation and vascular endothelial growth factor 165release in hepatocellular cancer 显示文摘 | Ferroni P Spila A D Alssandro R | 2011 | Clin Chim Acta2011，412，56： | 1 |
| 19 | Gabapentin (GBP) in panic disorders-case report 显示文摘 | Spila B Szumillo A | 2006 | Psychiatr Pol2006，40，： | 1 |
| 20 | 显示文摘 | Panero S Spila E Scrosati B | 1996 | J Electrochem Soc1996，143，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员